Praxis precision medicines announces positive topline results from prax-628 phase 1 study enabling best-in-class profile

Prax-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the mes ec50; prax-628 predicted therapeutic range at least 3-fold wider than current market leader based on mes model
PRAX Ratings Summary
PRAX Quant Ranking